MCID: PLY020
MIFTS: 48

Polyradiculoneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Polyradiculoneuropathy

MalaCards integrated aliases for Polyradiculoneuropathy:

Name: Polyradiculoneuropathy 12 51 41 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4308
MeSH 41 D011129
SNOMED-CT 64 128078004
UMLS 69 C0032587

Summaries for Polyradiculoneuropathy

MalaCards based summary : Polyradiculoneuropathy is related to chronic inflammatory demyelinating polyradiculoneuropathy and guillain-barre syndrome. An important gene associated with Polyradiculoneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and spinal cord, and related phenotypes are cellular and homeostasis/metabolism

Wikipedia : 72 Polyradiculoneuropathy describes a condition in which polyneuropathy and polyradiculopathy occur... more...

Related Diseases for Polyradiculoneuropathy

Diseases related to Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 213)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyradiculoneuropathy 32.3 ALB CXCR4 IFNG IL17A MBP MPZ
2 guillain-barre syndrome 31.0 ALB MBP MPZ PMP2 PMP22 TNFRSF1A
3 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.2 IFNG IL10 IL17A
4 hereditary neuropathy with liability to pressure palsy 30.2 MPZ PMP22
5 polyneuropathy 30.0 MBP MPZ PMP22
6 myasthenia gravis 30.0 IFNG IL10 MBP
7 neuropathy, hereditary, with liability to pressure palsies 29.9 MPZ PMP22
8 hereditary neuropathies 29.9 MBP MPZ PMP22
9 meningitis 29.9 ALB IFNG IL10
10 neurosyphilis 29.8 IL10 IL17A
11 chronic graft versus host disease 29.7 ALB IFNG IL10
12 helicobacter pylori infection 29.5 CCL5 IFNG IL10
13 autoimmune disease 29.4 IFNG IL10 IL17A MBP
14 interstitial lung disease 29.4 CCL5 IFNG IL10
15 radiculopathy 29.4 CCL5 IL10 IL17A
16 allergic hypersensitivity disease 29.4 CCL5 IFNG IL10
17 dermatitis, atopic 29.1 CCL5 IFNG IL10 IL17A
18 neuritis 28.9 CCL5 IFNG MBP MPZ PMP2 PMP22
19 systemic lupus erythematosus 28.7 ALB CCL5 IFNG IL10 IL17A TNFRSF1A
20 malaria 28.7 ALB CCL5 IFNG IL10 IL17A
21 psoriasis 28.4 CCL5 IFNG IL10 IL17A TNFRSF1A
22 rheumatoid arthritis 28.4 CCL5 IFNG IL10 IL17A TNFRSF1A
23 multiple sclerosis 28.1 CCL5 IFNG IL10 IL17A MBP MPZ
24 inflammatory bowel disease 27.2 ALB CCL5 IFNG IL10 IL17A TBX21
25 polyradiculoneuropathy associated with igg/iga/igm monoclonal gammopathy without known antibodies 11.9
26 chronic inflammatory demyelinating polyneuropathy 11.6
27 guillain-barre syndrome, familial 11.2
28 chronic inflammatory demyelinating polyneuritis 11.0
29 subacute inflammatory demyelinating polyneuropathy 11.0
30 chronic polyradiculoneuritis 10.9
31 charcot-marie-tooth neuropathy type 1 10.6 MPZ PMP22
32 foot drop 10.5 MPZ PMP22
33 charcot-marie-tooth disease, demyelinating, type 1f 10.5 MPZ PMP22
34 charcot-marie-tooth disease, demyelinating, type 1b 10.5 MPZ PMP22
35 charcot-marie-tooth disease, axonal, type 2b 10.4 MPZ PMP22
36 hyperlucent lung 10.4 IFNG IL10
37 niemann-pick disease, type a 10.4 MBP MPZ
38 trichosporonosis 10.4 IFNG IL17A
39 congenital hypomyelination neuropathy 10.4 MBP MPZ PMP22
40 sporotrichosis 10.4 IFNG IL10
41 pelizaeus-merzbacher disease 10.3 MBP MPZ PMP22
42 immune suppression 10.3 IFNG IL10
43 baylisascariasis 10.3 IFNG IL10
44 african tick-bite fever 10.3 CCL5 IFNG
45 clonorchiasis 10.3 IFNG IL10
46 pericardial tuberculosis 10.3 IFNG IL10
47 myositis fibrosa 10.3 IFNG IL17A
48 tuberculoid leprosy 10.3 IFNG IL10
49 roussy-levy hereditary areflexic dystasia 10.3 MPZ PMP22
50 aspiration pneumonia 10.3 ALB IL17A

Graphical network of the top 20 diseases related to Polyradiculoneuropathy:



Diseases related to Polyradiculoneuropathy

Symptoms & Phenotypes for Polyradiculoneuropathy

MGI Mouse Phenotypes related to Polyradiculoneuropathy:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.29 PMP22 PRF1 MBP TBX21 MPZ GATA2
2 homeostasis/metabolism MP:0005376 10.26 PMP2 IL17A PRF1 MBP TBX21 MPZ
3 hematopoietic system MP:0005397 10.24 IL17A PRF1 MBP TBX21 MPZ IFNG
4 endocrine/exocrine gland MP:0005379 10.18 IL17A PRF1 IL10 GATA2 ALB IFNG
5 growth/size/body region MP:0005378 10.16 IL10 PMP22 IL17A PRF1 MBP GATA2
6 immune system MP:0005387 10.16 IL17A PRF1 MBP IL10 MPZ CCL5
7 mortality/aging MP:0010768 10.14 MPZ PMP22 IL17A PRF1 MBP IL10
8 digestive/alimentary MP:0005381 10.08 IL10 IL17A ALB IFNG CXCR4 TBX21
9 nervous system MP:0003631 10 PMP2 PMP22 PRF1 MBP TBX21 MPZ
10 liver/biliary system MP:0005370 9.91 IL10 PRF1 GATA2 ALB IFNG TNFRSF1A
11 neoplasm MP:0002006 9.87 PRF1 TBX21 IL10 ALB IFNG CXCR4
12 muscle MP:0005369 9.85 IL10 PMP22 ALB IFNG CXCR4 TNFRSF1A
13 renal/urinary system MP:0005367 9.63 IL17A GATA2 ALB IFNG CXCR4 TNFRSF1A
14 reproductive system MP:0005389 9.61 PMP22 PRF1 MBP MPZ IL10 GATA2
15 respiratory system MP:0005388 9.1 IL10 IL17A IFNG CXCR4 TBX21 TNFRSF1A

Drugs & Therapeutics for Polyradiculoneuropathy

Drugs for Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2
2 gamma-Globulins Phase 4,Phase 3,Phase 2
3 Immunoglobulins Phase 4,Phase 3,Phase 2
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
6
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
7
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 3 24280-93-1 446541
9
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
10 Fingolimod Hydrochloride Phase 3
11 Immunosuppressive Agents Phase 3,Phase 2
12 3,4-diaminopyridine Phase 3
13 Potassium Channel Blockers Phase 3,Phase 2
14 Anti-Inflammatory Agents Phase 3,Phase 2
15 Antineoplastic Agents, Hormonal Phase 3,Phase 2
16 glucocorticoids Phase 3,Phase 2
17 Hormone Antagonists Phase 3,Phase 2
18 Hormones Phase 3,Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
20 Pharmaceutical Solutions Phase 3,Phase 2
21 Anti-Infective Agents Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 3
23 Antibiotics, Antitubercular Phase 3
24 Antitubercular Agents Phase 3
25
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
26
4-Aminopyridine Approved Phase 2 504-24-5 1727
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28 Complement System Proteins Phase 2
29 Adjuvants, Immunologic Phase 2
30 Antiviral Agents Phase 2
31 Interferon-beta Phase 2
32 interferons Phase 2
33 Antioxidants Phase 2
34 Micronutrients Phase 2
35 Protective Agents Phase 2
36 Thioctic Acid Phase 2
37 Trace Elements Phase 2
38 Vitamin B Complex Phase 2
39 Vitamins Phase 2
40 Alpha-lipoic Acid Nutraceutical Phase 2
41 Folate Nutraceutical Phase 2
42 Vitamin B9 Nutraceutical Phase 2
43
Citric Acid Approved, Nutraceutical, Vet_approved 77-92-9 311
44 Vaccines
45 Anticoagulants
46 Calcium, Dietary
47 Chelating Agents
48 Antibodies, Anti-Idiotypic
49 Citrate Nutraceutical

Interventional clinical trials:

(show top 50) (show all 69)

# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
3 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
4 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
5 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
6 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
7 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
8 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
9 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
10 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
11 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
12 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
13 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
14 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
15 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
16 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
17 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
18 Interest of Mycophenolate for CIDP Weaning Active, not recruiting NCT02494505 Phase 3 Mycophenolate Mofetil;placebo
19 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
20 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
21 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
22 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
23 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
25 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
26 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
27 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Completed NCT02780570 Phase 2
28 Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
29 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
30 Early Mechanical Ventilation for Guillain Barré Syndrome Completed NCT00167622 Phase 2
31 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
32 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
33 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
34 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
35 A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Active, not recruiting NCT03275740 Phase 1 PF-06755347;Placebo comparator
36 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
37 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
38 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
39 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
40 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
41 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
42 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
43 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
44 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678
45 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
46 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
47 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome Completed NCT02883270
48 Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS) Completed NCT01306578 IVIG
49 Safety Study of GBS Following Menactra Meningococcal Vaccination Completed NCT00575653
50 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200

Search NIH Clinical Center for Polyradiculoneuropathy

Cochrane evidence based reviews: polyradiculoneuropathy

Genetic Tests for Polyradiculoneuropathy

Anatomical Context for Polyradiculoneuropathy

MalaCards organs/tissues related to Polyradiculoneuropathy:

38
Brain, Skin, Spinal Cord, T Cells, Thyroid, Tongue, Kidney

Publications for Polyradiculoneuropathy

Articles related to Polyradiculoneuropathy:

(show top 50) (show all 522)
# Title Authors Year
1
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
2
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. ( 29435815 )
2018
3
Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249367 )
2018
4
Immunohistochemistry and electrophysiological findings in swine abattoir workers with immune-mediated polyradiculoneuropathy. ( 29406910 )
2018
5
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018
6
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. ( 28481421 )
2017
7
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. ( 28084646 )
2017
8
Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). ( 29119642 )
2017
9
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. ( 28382108 )
2017
10
Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. ( 28786217 )
2017
11
Prospective comparison of acute motor axonal neuropathy and acute inflammatory demyelinating polyradiculoneuropathy in 140 children with Guillain-BarrAc syndrome in India. ( 29053890 )
2017
12
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29089585 )
2017
13
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 29185258 )
2017
14
Early electrophysiological findings in acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barre syndrome in the Pakistani populationA -A a comparison with global data. ( 29091318 )
2017
15
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29092099 )
2017
16
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. ( 28646568 )
2017
17
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. ( 29145880 )
2017
18
Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. ( 28337614 )
2017
19
Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors. ( 28432982 )
2017
20
ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. ( 29065233 )
2017
21
Chronic inflammatory demyelinating polyradiculoneuropathy and anesthesia: a case series. ( 28936613 )
2017
22
Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 28522988 )
2017
23
Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. ( 28215575 )
2017
24
Subacute demyelinating polyradiculoneuropathy complicating Epstein-Barr virus infection in GATA2 haploinsufficiency. ( 28093780 )
2017
25
Acute Inflammatory Demyelinating Polyradiculoneuropathy Secondary to Ifosfamide. ( 28816726 )
2017
26
Lewis-Sumner syndrome in a patient with rheumatoid arthritis: Link between rheumatoid arthritis and demyelinating polyradiculoneuropathies. ( 28363822 )
2017
27
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29086018 )
2017
28
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. ( 27781132 )
2016
29
A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon I+-2a in a patient with chronic hepatitis B virus infection. ( 27680223 )
2016
30
Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. ( 27230584 )
2016
31
Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. ( 27838091 )
2016
32
A case of severe chronic inflammatory demyelinating polyradiculoneuropathy with monoclonal gammopathy of undetermined significance with alternating immunoglobulin class to IgM from IgA. ( 27580763 )
2016
33
Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand. ( 27113227 )
2016
34
Acute inflammatory demyelinating polyradiculoneuropathy in a newborn infant. ( 27238765 )
2016
35
Fatigue, Pain, Anxiety and Depression in Guillain-BarrAc Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27077919 )
2016
36
Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis. ( 28607734 )
2016
37
A case of a 17-year-old male with neurofascin-155 antibody-positive chronic inflammatory demyelinating polyradiculoneuropathy presenting with tremor and ataxia. ( 27580761 )
2016
38
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. ( 27902997 )
2016
39
Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response. ( 27175635 )
2016
40
IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. ( 27852440 )
2016
41
Evolution of hepatitis E virus-associated meningo-polyradiculoneuropathy on ribavirin. ( 27470489 )
2016
42
Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 26977594 )
2016
43
Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. ( 26873805 )
2016
44
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. ( 28070468 )
2016
45
Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27211560 )
2016
46
Intravenous Immunoglobulins Lower Inflammatory Gene Expression in Skin Biopsies of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. ( 27286956 )
2016
47
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-BarrAc syndrome: a case report. ( 27380808 )
2016
48
Motor unit number index (MUNIX): Is it relevant in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)? ( 26750580 )
2016
49
Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. ( 27468083 )
2016
50
Giant nerves in chronic inflammatory polyradiculoneuropathy. ( 27463360 )
2016

Variations for Polyradiculoneuropathy

Expression for Polyradiculoneuropathy

Search GEO for disease gene expression data for Polyradiculoneuropathy.

Pathways for Polyradiculoneuropathy

Pathways related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 CXCR4 IFNG IL10 IL17A PRF1
2
Show member pathways
12.35 IFNG IL10 IL17A TBX21
3
Show member pathways
12.27 CCL5 IFNG IL10 TNFRSF1A
4
Show member pathways
11.91 IFNG IL10 IL17A
5 11.84 ALB CXCR4 GATA2
6 11.74 CCL5 CXCR4 GATA2 IFNG IL10 IL17A
7 11.68 MBP MPZ PMP22
8 11.63 CXCR4 IFNG IL10
9 11.59 CCL5 IFNG IL17A
10
Show member pathways
11.47 IFNG IL10 IL17A TBX21
11 11.27 CCL5 IL10 TNFRSF1A
12 11.16 IFNG IL10 IL17A TBX21
13
Show member pathways
11.1 IFNG IL10 TNFRSF1A
14 11 IFNG IL17A TBX21
15 10.98 IFNG IL10
16 10.96 IFNG PRF1
17 10.88 IFNG PRF1 TBX21

GO Terms for Polyradiculoneuropathy

Cellular components related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 compact myelin GO:0043218 8.96 MBP PMP22
2 myelin sheath GO:0043209 8.92 ALB MBP MPZ PMP2

Biological processes related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.85 CXCR4 IFNG IL17A PRF1 TNFRSF1A
2 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 CCL5 IFNG TNFRSF1A
3 inflammatory response GO:0006954 9.55 CCL5 CXCR4 IL10 IL17A TNFRSF1A
4 positive regulation of interleukin-6 secretion GO:2000778 9.51 IL17A MBP
5 myelination GO:0042552 9.5 MBP MPZ PMP22
6 positive regulation of osteoclast differentiation GO:0045672 9.49 IFNG IL17A
7 dendritic cell chemotaxis GO:0002407 9.48 CCL5 CXCR4
8 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.43 IL10 MBP
9 positive regulation of interleukin-23 production GO:0032747 9.37 IFNG IL17A
10 positive regulation of killing of cells of other organism GO:0051712 9.26 IFNG PRF1
11 response to virus GO:0009615 9.26 CCL5 CXCR4 IFNG TBX21
12 immune response GO:0006955 9.1 CCL5 IFNG IL10 IL17A MBP TNFRSF1A

Molecular functions related to Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.77 ALB CCL5 CXCR4 GATA2 IFNG IL10
2 fatty acid binding GO:0005504 9.16 ALB PMP2
3 cytokine activity GO:0005125 8.92 CCL5 IFNG IL10 IL17A

Sources for Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....